Tempus AI, Inc. Class A (TEM)

Tempus AI went public on the Nasdaq on June 14, 2024, under the ticker symbol TEM. In June 2024, the stock surged by 55.7% shortly after its IPO. In January 2025, Investing.com identified Tempus AI as significantly undervalued, followed by an 87% return in 10 months, and the stock surged 45% in a week after the launch of its AI app, Olivia. In February 2025, the acquisition of Ambry Genetics was finalized. In March 2025, Tempus acquired Deep 6 AI. In May 2025, the stock plunged after a report from short seller Spruce Point Capital. In August 2025, Tempus announced the acquisition of Paige AI. In October 2025, TEM reached its all-time high of $104.32. In November 2025, despite reporting Q3 financial results that beat estimates and boosting its 2025 revenue guidance, Tempus AI's stock was down approximately 7% in after-hours trading.

There is no explicit information indicating specific demand seasonality for Tempus AI's products and services. Demand is more influenced by broader healthcare trends, technological advancements, and strategic initiatives rather than predictable seasonal fluctuations.

Tempus AI is a health technology company founded in 2015 that uses data and AI to advance precision medicine. It operates in computer software, programming, data processing, and decision/risk analysis. The company's core business revolves around three main product lines: Genomics, Data, and Apps. Its major products and services include high-throughput genomic sequencing, data-driven solutions for drug discovery and development, and AI-driven applications that enhance lab test accuracy and personalization. The company's platform is described as an operating system for precision medicine, utilizing AI to analyze diverse health data across multiple medical fields.

Tempus AI is headquartered in Chicago, Illinois, US, with a global ambition to deliver AI-driven precision medicine across all disease areas globally. In June 2024, Tempus AI and SoftBank formed a joint venture in Japan called SB Tempus, focused on developing personalized treatment recommendations through AI analysis of medical data. The company also seeks to expand patient access to clinical research across the United States.

Tempus AI's brand reputation was impacted in May 2025 when Spruce Point Capital published a report alleging concerns regarding Tempus's leadership and AI capabilities. Tempus AI responded to these accusations, stating that the report was riddled with inaccuracies and failed to acknowledge the company's strong financial performance and growth.

Tempus AI has a diverse ownership structure including institutional owners, individual owners (insiders), and retail investors. As of September 30, 2025, Tempus AI has 617 institutional owners holding a total of 107,673,453 shares. Individual insiders own a significant portion of the company, with CEO Eric Lefkofsky being the largest shareholder. Retail investors hold approximately 11% to 22.23% of Tempus AI, Inc. Class A stock.